Exhibit 10.5
FIRST AMENDMENT TO THE
AMENDED AND RESTATED
LEAD DMD PRODUCT MANUFACTURING & SUPPLY AGREEMENT
This first amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement (“First Amendment”) by and between Sarepta Therapeutics Three, LLC (“Sarepta”), and Catalent Maryland, Inc. (“Catalent”).
WHEREAS, Sarepta and Catalent entered into that certain Amended and Restated Lead DMD Product Manufacturing & Supply Agreement dated November 28, 2022 (the “Agreement”); and
WHEREAS, Sarepta and Catalent desire to amend the Agreement to correct a scrivener’s error therein;
NOW, THEREFORE, the Parties agree as follows:
1
DOCPROPERTY DOCXDOCID DMS=InterwovenIManage Format=<<NUM>>_<<VER>> PRESERVELOCATION \* MERGEFORMAT 137305665_2
IN WITNESS WHEREOF, the parties have caused their respective duly authorized Representatives to execute this First Amendment effective as of November 28, 2022.
CATALENT MARYLAND, INC SAREPTA THERAPEUTICS THREE, LLC
By: /s/ Manja Boerman By: /s/ Adam Hopkin
Name: Manja Boerman Name: Adam Hopkin
Title: President, Cell & Gene Therapy Title: Manager
2
DOCPROPERTY DOCXDOCID DMS=InterwovenIManage Format=<<NUM>>_<<VER>> PRESERVELOCATION \* MERGEFORMAT 137305665_2